1. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe
- Author
-
Kai Ulbricht, Franz-Christoph Bange, Reinhold-Ernst Schmidt, Matthias Stoll, and Markus Rihl
- Subjects
Adult ,Male ,Microbiology (medical) ,medicine.medical_specialty ,Sodium stibogluconate ,Phosphorylcholine ,Antiprotozoal Agents ,Human immunodeficiency virus (HIV) ,Leishmaniasis, Cutaneous ,HIV Infections ,medicine.disease_cause ,Acquired immunodeficiency syndrome (AIDS) ,Recurrence ,Amphotericin B ,Germany ,Hiv infected ,parasitic diseases ,medicine ,Animals ,Humans ,Post-kala-azar dermal leishmaniasis ,Miltefosine ,business.industry ,Leishmaniasis ,medicine.disease ,Dermatology ,Europe ,Treatment Outcome ,Infectious Diseases ,Visceral leishmaniasis ,Antimony Sodium Gluconate ,Liposomes ,Immunology ,Leishmaniasis, Visceral ,business ,medicine.drug - Abstract
We present a 42-year-old man who was admitted with worsening of his general condition and facial skin lesions. He had previously been diagnosed with HIV infection and visceral leishmaniasis (VL). Diagnostic work-up revealed a new relapse of VL paralleled by the diagnosis of post-kala-azar dermal leishmaniasis (PKDL). The patient was treated with IV liposomal amphotericin B as well as sodium stibogluconate followed by oral hexadecylphosphocholine (miltefosine) over a period of 9 months. PKDL lesions began to disappear after 8 months of treatment. In addition, severe and relapsing VL so far remains in remission. This case demonstrates successful treatment of PKDL and relapsing VL in a Western European patient with HIV infection.
- Published
- 2006